The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation.
The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation. Oncogene (2003 Oncogene ( ) 22, 456-460. doi:10.1038 Keywords: ID2; MYC; MYCN; neuroblastoma; prognosis Neuroblastoma is a childhood tumor derived from sympathetic nervous system precursor cells (Hoehner et al., 1996 (Hoehner et al., , 1998 . Detailed cytogenetic characterization indicates that neuroblastoma can be divided into subgroups based on their genetic aberrations, but the molecular events leading to malignant transformation of these neural crest-derived precursor cells are not known in any detail. One of these genetic subgroups is characterized by the presence of MYCN amplification, most often in combination with deletion of 1p and distal 17q gain (Maris and Matthay, 1999; Bown, 2001) . Tumors belonging to this type of neuroblastoma are often refractory to current treatment protocols and are associated with poor survival. MYCN is the only gene within the studied 2p24 MYCN amplicon, which is consistently amplified and overexpressed, suggesting that high MYCN expression plays a key role in the development of this and possibly also other neuroblastoma subtypes (Reiter and Brodeur, 1998; De Preter et al., 2002) . Although MYCN as well as the other family members MYC and MYCL stimulates cell growth and cell cycle progression, an additional, more specific, role for MYCN in differentiating sympathetic neuroblasts has been suggested (Sawai et al., 1993; Wakamatsu et al., 1997) . The transforming properties of the MYC genes have been extensively documented. In particular, overexpression of MYCN in tyrosine hydroxylase expressing cells in transgenic mice has been shown to result in neuroblastomas in a dose-dependent manner (Weiss et al., 1997) .
In view of the strong correlation between MYCN amplification and poor prognosis in neuroblastoma, which was demonstrated already some 20 years ago, it is remarkable that the molecular consequences of this phenomenon remain elusive. Therefore, recent studies demonstrating that ID2 (inhibitor of DNA binding/ differentiation) is a direct transcriptional target of both MYCN and MYC contributed to our understanding of the molecular link between MYCN overexpression and aggressive neuroblastoma behavior (Lasorella et al., 2000) . The observations are of particular importance as ID2 potentially affects two major aspects of aggressive tumor cell behavior. First, proliferation would be promoted as ID2 activity in many cell systems induces proliferation primarily via interaction with the RB pathway (reviewed in Zebedee and Hara, 2001; Lasorella et al, 2001) . Secondly, differentiation would be affected since elevated levels of ID2 in neuroblastoma indirectly would inhibit the activity of tissue-specific basic helix-loop-helix (bHLH) transcription factors like ASCL1 and HAND2 (Jo¨gi et al., 2002a) . The latter could result in differentiation-arrested tumor cells, which would be in keeping with the well-established fact that highly malignant neuroblastomas (approximately 50% with MYCN amplification) have an immature phenotype. In a follow-up study, Lasorella et al. (2002) added clinical relevance to their initial findings by demonstrating that high ID2 expression in neuroblastoma specimens, detected by immunohistochemistry, correlated to negative outcome and high MYCN protein levels. In our laboratories, however, independent initial observations and a subsequent series of more detailed and carefully controlled analyses could neither confirm the proposed correlation between MYCN and ID2 expressions, nor the prognostic power of ID2 expression.
The triggering experiments included expression analysis of MYCN, MYC, and ID2 mRNA levels in eight neuroblastoma cell lines and subclones, MYCN transfected SK-N-SH cells (Judware and Culp, 1995) (Figure 1a) , and in the SH-EP cell line stably transfected with a tetracycline controllable MYCN expression construct (Lutz et al., 1996) (Figure 1b) . Northern blot and quantitative RT-PCR results showed no correlation between the expression levels of ID2 and MYCN or MYC (Figure 1a, b) . However, the previously reported inverse correlation between MYCN and MYC expression (Breit and Schwab, 1989 ) was confirmed (with high MYCN expression in the amplified cell lines LA-N-1, LA-N-2, SK-N-BE(2), IMR-32, and KCN69n, and Real-time quantitative SYBR Green I RT-PCR analysis of ID2, MYCN, and MYC in SH-EP/Tet-off cells (treated for 24 h with 0, 1, and 100 ng/ml tetracycline) and six neuroblastoma cell lines using a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) (expression level7s.e.m; derived from two independent cell cultures and RNA extracts). DNase treatment, cDNA synthesis, primer design, and SYBR Green I RT-PCR were performed as described (Vandesompele et al., 2002a) . The geometric mean of four housekeeping genes (UBC, SDHA, HPRT1, and GAPD) was used for normalization of each reaction according to Vandesompele et al. (2002b) . Primer sequences are available in the public RTPrimerDB database (http:// www.realtimeprimerdatabase.ht.st) (gene : primer-ID; MYCN : 187, MYC : 18, ID2 : 102, UBC : 8, SDHA : 7, HPRT1 : 5, and GAPD : 3). All gene quantifications were characterised by absence of primer dimers during amplification, a standard curve with an excellent slope over four orders of magnitude, and the presence of one sharp amplicon peak during melting curve analysis. Note that the expression levels between the different genes cannot be compared. (d) . From parallel cultures of the six cell lines used in panel c, SK-N-SH, IMR-32, NGP, SK-N-AS, SK-N-FI, and LA-N-1, cells were harvested and analysed for MYCN, MYC, and ID2 protein levels by Western blot analysis. In total, 40 mg of whole cell protein lysate was separated in a 10% SDS-PAGE gel. The following primary antibodies and antisera were used: anti-GAPD (Chemicon International, Temecula, CA, USA), anti-MYC (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ID2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-MYCN (BD Pharmingen, Franklin Lakes, NJ, USA). HRP-coupled secondary antibodies were supplied by Jackson ImmunoResearch Laboratories (West Grove, PA, USA) and Amersham Pharmacia Biotech (Uppsala, Sweden). Rainbow RPN 756 (Amersham Pharmacia Biotech, Uppsala, Sweden) was used as the molecular weight marker. Cells analysed in panels a, c, and d were seeded at day À1, given fresh medium at day 0 and harvested at day 1, unless stated otherwise ID2 and MYCN expression in neuroblastoma J Vandesompele et al hardly or no detectable MYCN expression in the MYCN single-copy cell lines SK-N-SH and SH-SY5Y, and the inverse pattern for MYC expression). Although the individual contribution of MYCN or MYC to the ID2 expression level is difficult to assess in cell lines where both genes are expressed, we noted that among the MYCN-amplified cell lines, where the contribution of MYC expression should be low, also no covariation in MYCN and ID2 expression was observed. Notably, the LA-N-2 cells had comparatively low MYCN and high ID2 expression levels, while in, for instance, SK-N-BE(2) cells an inverse pattern was seen (Figure 1a) . The inverse relation between MYCN and MYC expression and lack of correlation between MYCN and ID2 was further demonstrated in SK-N-SH cells constitutively overexpressing MYCN (SKMYC2 cells), and in SH-EP/ tet-off cells conditionally overexpressing MYCN (Figure  1a , b).
As our initial results contrasted the reported data (Lasorella et al., 2000 (Lasorella et al., , 2002 , we decided to reinvestigate the potential link between MYCN and ID2 expression in neuroblastoma, by mRNA and protein analysis of six of the cell lines analysed by Lasorella et al. (2000) , and by extensive mRNA expression measurements in a large series of additional cell lines and primary tumors. Again, there was no apparent correlation between MYC(N) and ID2 expression in the six cell lines when analysed at the mRNA level (Figure 1c) . Similarly, ID2 protein levels did not covary with either MYCN or MYC protein when analysed in lysates derived from parallel cultures used for the mRNA studies (Figure 1d ). Using quantitative RT-PCR, the expression analysis was extended to 28 neuroblastoma cell lines, of which seven were MYCN single-copy cell lines (Figure 2a-c) . There was no significant correlation between 1D2 and MYCN expressions. In contrast, we observed a significant (Figure 2g ). Previous observations (e.g. Jo¨gi et al., 2002b ) indicated that ID2 expression in cultured neuroblastoma cells is influenced by growth conditions, such as time after subculture and change of growth media. To test specifically if growth conditions might be one of the reasons for the discrepancies between our findings and published data (Lasorella et al., 2000) , we analysed the expression of ID2 and MYC(N) genes in neuroblastoma cells grown for 1, 3, or 5 days, with change of medium at day 3. ID2 mRNA levels in all tested cell lines decreased substantially between days 1 and 3, while expression increased at day 5, 2 days after the change of medium. This is in contrast to the MYCN, MYC, and GAPD mRNA levels that were essentially unaffected by the growth conditions tested (Figure 3) . We conclude that ID2 expression levels vary considerably depending on the experimental conditions used, an observation in keeping with the reported ID2 oscillations during the cell cycle (Zebedee and Hara, 2001) .
From a clinical perspective, the most important finding by Lasorella et al. (2002) is the association between high ID2 protein immunoreactivity and poor prognosis in neuroblastoma specimens. To test if there is a similar correlation at the mRNA level, RNA prepared from 27 neuroblastoma tumors (12 stages 1, 2 and 4S, and 15 stages 3 and 4), seven of them with MYCN amplification, was analysed with quantitative RT-PCR for ID2, MYCN, and MYC expressions. Interestingly enough, while MYCN and ID2 expressions did not correlate significantly, there was a positive correlation between MYC and ID2 expressions in both single-copy and amplified tumors (Figure 2d-g ). To address the prognostic value of 1D2 expression, 32 additional primary tumors were studied, to have an unselected cohort of 59 patients (11 with MYCN amplification; 28 stage 1/2/4S, and 31 stage 3/4 patients), which is representative for the general neuroblastoma population as age at diagnosis (P ¼ 0.013), stage (Po0.0001) and MYCN-amplification (Po0.0001) status are clear prognostic markers according to Kaplan-Meier survival analysis. Both the median and mean expression levels were used as a cutpoint to dichotomize the patient population, but none attributed prognostic power to ID2 mRNA expression (P>0.05), although there was a tendency among patients with lower ID2 mRNA levels to have a more favorable prognosis, as exemplified in Figure 4a . Upon division of our patient cohort into four quartiles (from low-to-high expression), no quartile was associated with worse prognosis. The lack of significant survival difference between the highest and lowest quartiles clearly indicates that ID2 mRNA is not a Figure 3 Alteration of ID2 expression over time. Northern blot analysis of MYCN, MYC, and ID2 expressions in SK-N-SH, SK-N-BE(2), IMR-32, and KCN-69n cells. Total RNA (15 mg) from cells harvested on days 1, 3, and 5 was analysed with GAPD mRNA levels as a loading control. Cells were seeded at day À1 and given fresh medium at day 0, and for day 5 cells also at day 3 prognostic marker (P ¼ 0.14). As expected, MYCN amplification did predict a poor outcome (Figure 4b) .
We conclude that ID2 and MYCN expressions do not correlate in neuroblastoma tumors or cell lines. However, we did find a correlation between the expression of 1D2 and MYC in tumors and in MYCN single-copy cell lines. This is interesting in the light of the ID2 gene reporter assays presented by Lasorella et al. (2000) , where they demonstrate that both MYC and MYCN activate the ID2 promoter in a fibroblast setting. To our knowledge, the in vivo binding of MYCN to the ID2 promoter has not been shown, and our data strongly suggest that MYCN, probably in contrast to MYC, is not promoting ID2 expression in neuroblastoma. In agreement with the lack of correlation between MYCN and ID2 expression levels, we found no significant prognostic information in stratifying high versus low ID2-expressing tumors. Our conclusion is based on ID2 mRNA levels, while Lasorella et al. (2002) have analysed ID2 protein levels. To reconcile these observations, one would have to assume a post-transcriptional regulation of ID2. However, in such case the mechanisms regulating the ID2 protein levels must be independent of MYCN expression. Thus, further studies are needed to clarify the reason for the remarkable differences between the present and published data.
